1.09
-0.08 (-6.84%)
| Previous Close | 1.17 |
| Open | 1.15 |
| Volume | 4,490,533 |
| Avg. Volume (3M) | 5,262,739 |
| Market Cap | 216,036,928 |
| Price / Earnings (Forward) | 1.34 |
| Price / Sales | 0.870 |
| Price / Book | 98.42 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -59.03% |
| Operating Margin (TTM) | -34.00% |
| Diluted EPS (TTM) | -0.850 |
| Quarterly Revenue Growth (YOY) | -52.80% |
| Current Ratio (MRQ) | 1.18 |
| Operating Cash Flow (TTM) | -100.11 M |
| Levered Free Cash Flow (TTM) | -80.85 M |
| Return on Assets (TTM) | -7.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Esperion Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 0.58% |
| % Held by Institutions | 59.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Meditor Group Ltd | 30 Sep 2024 | 3,791,300 |
| Indaba Capital Management, L.P. | 31 Mar 2025 | 3,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (HC Wainwright & Co., 1,367.89%) | Buy |
| Median | 4.00 (266.97%) | |
| Low | 3.00 (Goldman Sachs, 175.23%) | Hold |
| Average | 7.67 (603.67%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 0.970 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Jun 2025 | 16.00 (1,367.89%) | Buy | 1.09 |
| 25 Apr 2025 | 16.00 (1,367.89%) | Buy | 0.920 | |
| Needham | 07 May 2025 | 4.00 (266.97%) | Buy | 0.870 |
| 25 Apr 2025 | 5.00 (358.72%) | Buy | 0.920 | |
| Goldman Sachs | 17 Apr 2025 | 3.00 (175.23%) | Hold | 0.950 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |